<DOC>
	<DOCNO>NCT00569153</DOCNO>
	<brief_summary>The purpose study determine safety tolerability TAK-700 patient asymptomatic metastatic , androgen independent prostate cancer .</brief_summary>
	<brief_title>Safety Study TAK-700 Subjects With Prostate Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Subject male least 18 year age . Subject histologically cytologicallyconfirmed prostate adenocarcinoma metastatic , progressive disease androgen deprivation therapy . Subject radiographdocumented ( compute tomography , magnetic resonance image xray ) metastatic disease . Subject undergone orchiectomy expect continue receive luteinizing hormonereleasing hormone analogue therapy , testosterone level &lt; 50 ng/dL screening . Subject discontinue antiandrogen therapy ( within 30 day flutamide within 6 week others ) prior first dose study drug . Subject prostatespecific antigen level â‰¥5 ng/mL . Subject meet screen laboratory value specify protocol . Subject screen ejection fraction lower limit institutional normal range . Subject ECOG performance status 0 2 . Subject normal , opinion investigator , clinically insignificant , physical examination finding , ECG chest xray result . Subjects , even surgically sterilize ( ie , status postvasectomy ) , : agree practice effective barrier contraception entire study treatment period 4 month last dose study drug , agree completely abstain heterosexual intercourse . Subject know hypersensitivity TAK700 related compound . Subject receive prior therapy aminoglutethimide ketoconazole within 30 day prior first dose study drug . Subject receive prior chemotherapy prostate cancer . Subject receive investigational compound within 30 day prior first dose study drug . Subject receive prior herbal product know decrease prostatespecific antigen level ( eg , Saw Palmetto , PCSPES ) within 30 day prior first dose study drug . Subject receive radiation therapy prostate cancer within 30 day prior first dose study drug . Chronic therapy oral systemically administer corticosteroid , prednisone , within 30 day prior Screening . Chronic therapy define use corticosteroid 7 day within 30day period . Subject current spinal cord compression , current bilateral hydronephrosis , current bladder neck outlet obstruction . Subject history adrenal insufficiency . Subject history myocardial infarction , ischaemic symptomatic heart disease , cardiac arrhythmia thromboembolic event ( eg , deep vein thrombosis , pulmonary embolism , symptomatic cerebrovascular event ) , cardiac condition ( e.g. , pericardial effusion restrictive cardiomyopathy ) within 12 month prior first dose study drug . Subject symptom investigator deem related prostate cancer , i.e. , bone pain , pelvic pain . Subject history congestive heart failure ( New York Heart Association Class II great . Subject history another malignancy basal cell carcinoma state 1 squamous cell carcinoma skin , within last 5 year . Subject uncontrolled hypertension . Subject know HIV infection , chronic Hepatitis B C serious medical condition psychiatric illness might affect life expectancy make difficult successfully manage follow subject accord protocol . Subject unable understand verbal write English language certify translation institutional review board ( IRB ) approve informed consent provide . Subject unwilling unable comply protocol cooperate fully investigator site personnel .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Androgen-independent prostate cancer , metastatic</keyword>
</DOC>